PeterPLaCameraMD
Pulmonology • Boston, MAAsthma & COPD, Critical Care Medicine, Interstitial Lung Diseases, Occupational & Environmental Lung Disease
Assistant Professor, Medicine, Tufts Medical Center
Dr. LaCamera is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
736 Cambridge St.
St. Elizabeth's Pulmonary And Critical Care
Boston, MA 02135Phone+1 617-789-2545Fax+1 617-779-6798
Education & Training
Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 2001 - 2006
Boston University Medical CenterResidency, Internal Medicine, 1997 - 2000
University of Massachusetts Medical SchoolClass of 1997
Certifications & Licensure
MA State Medical License 1999 - 2026- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification athenaClinicals EHR, athenahealth, Inc, 2012-2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jul 30
Publications & Presentations
PubMed
- 3 citationsTRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial.Lorraine B Ware, Nima Soleymanlou, Danny Francis McAuley, Vicente Estrada, George A Diaz
Thorax. 2023-08-01 - Clinical Manifestations of Subjects With the Non-Specific Pulmonary Function Test Pattern.James Tasch, Samer Abujaber, Laith Hattar, Aju Jose, Lori Lyn Price
Open Respiratory Archives. 2023-06-15 - 3 citationsAnti-fibrotic therapy and lung transplant outcomes in patients with idiopathic pulmonary fibrosis.Todd L Astor, Hilary J Goldberg, Laurie D Snyder, Andrew Courtwright, Ramsey Hachem
Therapeutic Advances in Respiratory Disease. 2023-04-19
Press Mentions
#ATS2018 – Start of Anti-Fibrotic Therapy in Newly Diagnosed IPF Patients Can Depend on Physician Preference, Survey FindsMay 31st, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
